KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) FCF Margin (2009 - 2026)

Bristol Myers Squibb (BMY) reported FCF Margin of 6.59% for Q1 2026, down 853.0% year-over-year from 0.88% in Q1 2025, and down 48.64% on a QoQ basis from 12.83% in Q4 2025.

Bristol Myers Squibb (BMY) has 18 years of FCF Margin data on file, last reported at 6.59% in Q1 2026.

  • Quarterly FCF Margin fell 853.0% year-over-year to 6.59% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24.56% (down 291.0% YoY) and the FY2025 annual result came in at 26.65%, down 221.0% from the prior year.
  • FCF Margin fell to 6.59% in Q1 2026 per BMY's latest filing, from 12.83% in the prior quarter.
  • Across five years, FCF Margin topped out at 49.02% in Q3 2025 and bottomed at 6.59% in Q1 2026.
  • The 5-year median for FCF Margin is 25.95% (2022), against an average of 26.16%.
  • Peak annual rise in FCF Margin reached 1207 bps in 2025, while the deepest fall reached 2007 bps in 2025.
  • Tracing BMY's FCF Margin over 5 years: stood at 25.95% in 2022, then soared by 32 bps to 34.17% in 2023, then fell by 4 bps to 32.9% in 2024, then slumped by 61 bps to 12.83% in 2025, then sank by 49 bps to 6.59% in 2026.
  • Per Business Quant, the three latest BMY FCF Margin figures stand at 6.59% (Q1 2026), 12.83% (Q4 2025), and 49.02% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 15.19%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 6.09%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 23.76%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 17.97%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 17.14%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 34.87%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 93.16%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 6.59%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 6.59%
Dec 31, 2025 12.83%
Sep 30, 2025 49.02%
Jun 30, 2025 28.98%
Mar 31, 2025 15.12%
Dec 31, 2024 32.90%
Sep 30, 2024 44.29%
Jun 30, 2024 16.92%
Mar 31, 2024 21.49%
Dec 31, 2023 34.17%
Sep 30, 2023 40.21%
Jun 30, 2023 14.50%
Mar 31, 2023 23.75%
Dec 31, 2022 25.95%
Sep 30, 2022 30.67%
Jun 30, 2022 16.73%
Mar 31, 2022 30.55%
Dec 31, 2021 31.18%
Sep 30, 2021 42.98%
Jun 30, 2021 24.35%
Mar 31, 2021 32.97%
Dec 31, 2020 27.76%
Sep 30, 2020 20.06%
Jun 30, 2020 43.06%
Mar 31, 2020 34.79%
Dec 31, 2019 24.29%
Sep 30, 2019 39.39%
Jun 30, 2019 30.16%
Mar 31, 2019 20.03%
Dec 31, 2018 54.66%
Sep 30, 2018 18.54%
Jun 30, 2018 15.06%
Mar 31, 2018 18.02%
Dec 31, 2017 15.84%
Sep 30, 2017 27.62%
Jun 30, 2017 25.97%
Mar 31, 2017 11.56%
Dec 31, 2016 20.45%
Sep 30, 2016 21.60%
Jun 30, 2016 3.65%
Mar 31, 2016 -10.70%
Dec 31, 2015 13.97%
Sep 30, 2015 7.13%
Jun 30, 2015 -2.26%
Mar 31, 2015 12.13%
Dec 31, 2014 8.95%
Sep 30, 2014 20.30%
Jun 30, 2014 24.33%
Mar 31, 2014 13.09%
Dec 31, 2013 27.25%
Sep 30, 2013 22.85%
Jun 30, 2013 34.88%
Mar 31, 2013 -14.17%
Dec 31, 2012 15.77%
Sep 30, 2012 119.03%
Jun 30, 2012 22.98%
Mar 31, 2012 5.03%
Dec 31, 2011 26.29%
Sep 30, 2011 30.20%
Jun 30, 2011 18.75%
Mar 31, 2011 8.10%
Dec 31, 2010 28.76%
Sep 30, 2010 26.97%
Jun 30, 2010 20.30%
Mar 31, 2010 6.97%
Dec 31, 2009 22.81%
Sep 30, 2009 27.23%